News Formal

AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market

  • 📰 Reuters
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 97%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

AbbVie Inc said on Thursday it expects sales of its flagship rheumatoid arthritis drug Humira to decline 37% this year due to competition from cheaper biosimilars in the United States, but sees that stabilizing by the end of 2024.

Amjevita, the first biosimilar competition for Humira in the United States. At least seven others are expected to debut this summer.

Overall, Humira sales rose 4.6% to $5.58 billion, in line with estimates, lifted by growth in the U.S. market. Skyrizi sales of $1.58 billion beat analysts' estimates of $1.52 billion, while Rinvoq missed with $770 million in sales compared with expectations of $816.14 million.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 2. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し